Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected

Executive Summary

The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.

You may also be interested in...



NICE Stuns Merck With Demand For Additional Daxas Trial

NICE says it wants Merck to carry out an additional clinical trial of Daxas in conjunction with triple therapy for COPD, if the company is to get its drug into the NHS.

Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta

Human Genome Sciences escaped a boxed label warning and a Risk Evaluation and Mitigation Strategy for its lupus drug Benlysta (belimumab), despite FDA expectations late in the review process that both would be needed.

Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta

Human Genome Sciences escaped a boxed label warning and a Risk Evaluation and Mitigation Strategy for its lupus drug Benlysta (belimumab), despite FDA expectations late in the review process that both would be needed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel